Sharemaestro Newsreel

Eton Pharmaceuticals (NASDAQ:ETON) Sets New 1-Year High Following Earnings Beat

Eton Pharmaceuticals (NASDAQ:ETON) reached a new 52-week high after reporting strong Q2 earnings, with EPS of $0.43 and revenue of $37.59 million, significantly beating analyst estimates. The stock surged 42%, supported by a maintained "Buy" rating and increased price targets from analysts like HC …

Eton Pharmaceuticals stock hits all-time high at 55.07 USD

Eton Pharmaceuticals Inc. stock reached an all-time high of $55.07, currently trading at $54.43, significantly above its 52-week high. Despite appearing overvalued by InvestingPro analysis, the company has seen a 139.44% appreciation over the last year, with its market capitalization at $1.12 billion and …

UBS Adjusts Price Target on Acadia Healthcare to $1.50 From $4.50, Keeps Neutral Rating

UBS has adjusted its price target for Acadia Healthcare (referred to as Accendra Health in the article) to $1.50, down from $4.50, while maintaining a Neutral rating on the stock. This adjustment follows similar downgrades and price target reductions from other firms like Citigroup …

Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 4.99% in BioXcel Therapeutics, Inc. (BTAI), amounting to 1,621,716 shares. These shares are held through Armistice Capital Master Fund Ltd., with Armistice Capital exercising shared voting and dispositive power as the investment …

BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7

BofA Securities has lowered its price target for Sana Biotechnology (SANA) to $6 from $7, as reported on August 14, 2026. This adjustment follows other recent news for the company, including its Q2 adjusted loss narrowing and its removal from several Russell Value Benchmarks …

Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting

Processa Pharmaceuticals shareholders approved several key proposals at their 2026 annual meeting on July 30, including an amendment to the 2019 Omnibus Incentive Plan to increase shares available for issuance by 200,000. Additionally, all six directors were re-elected, Cherry Bekaert, LLP was ratified as …

Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G/A for Artelo Biosciences (ARTL), reporting that they no longer beneficially own any common stock in the company. As of June 30, 2026, their ownership stake is 0 shares, representing 0.0% of the …

Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)

Are Investors Undervaluing Tenet Healthcare (THC) Right Now?

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in …

HCA Healthcare (HCA) Stock May Be 49% Undervalued As Wage Pressure Builds

HCA Healthcare (HCA) stock appears significantly undervalued according to both Discounted Cash Flow (DCF) and P/E ratio analyses, despite a 75.1% return over the past five years. The valuation gap could be influenced by recent concerns over rising labor costs, staffing pressures, and leadership …

Trinity Biotech secures $7m from Perceptive Advisors By Investing.com

Trinity Biotech (NASDAQ:TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, comprising $2.5 million in new debt and $4.5 million in capitalized interest. This funding will support the company's CGM+ continuous glucose monitoring platform, Trinovium subsidiary, and diagnostics …

Form 8K Lifeward Ltd. For: 14 August By Investing.com

This article reports on the filing of Form 8K by Lifeward Ltd. on August 14th. It appears to be a standard financial news brief from Investing.com, providing basic information about the filing and its publication details.

Quantum Biopharma Ltd. (CN:QNTM) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Development Challenges Pressure Investor Sentiment

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

EXEL|Exelixis Inc|Price:50.990|

Why Did Oscar Health (OSCR) Fall After Record Profit and a Guidance Hike?

Oscar Health, Inc. (NYSE:OSCR) shares closed 11.9% lower at $26.54 on August 6, even after the insurer reported its most profitable first half and raised its full-year outlook. Second-quarter revenue rose 70% year over year to $4.88 billion, while the company swung to net …

Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement

Trinity Biotech (NASDAQ: TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, and has regained compliance with Nasdaq's minimum bid price requirement. The investment, consisting of new debt funding and capitalized interest, aims to bolster liquidity for strategic …

Trinity Biotech Regains Nasdaq Compliance After 10 Days at $1 or More

Canton Strategic Holdings (CNTN) posts $66.6M loss amid big Canton Coin bet

Embecta (EMBC) Q3 2026 Earnings Call Transcript

Rapid Micro Biosystems (RPID) Q2 2026 Earnings Call Transcript

Why Is Capricor Therapeutics Stock Soaring Today? - Capricor Therapeutics (NASDAQ:CAPR)

Scholar Rock (SRRK) Stock Looks Priced At A Premium Today

Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call

Brown Advisory discloses 5.84M-share LMRI stake in Lumexa Imaging Holdings (LMRI)

Brown Advisory Inc., along with its subsidiaries, has disclosed a beneficial ownership of 5,842,935 shares of Lumexa Imaging Holdings, Inc. common stock, representing 6.08% of the class. The filing details sole voting power primarily held by Brown Advisory Inc. and Brown Advisory LLC, and …

DOCS|Doximity Inc|Price:26.375|Chg%:-0.215

JonesTrading Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock

Stifel cuts Nkarta stock price target on updated model By Investing.com

Stifel has lowered its price target for Nkarta Inc. (NASDAQ:NKTX) to $10 from $11, while maintaining a Buy rating, following the company's Q2 2026 earnings and an updated financial model. The adjustment comes after discussions with Nkarta's management regarding patient enrollment progress in its …

Tenet Healthcare Corporation (THC) Hits Fresh High: Is There Still Room to Run?

Shares of Tenet Healthcare (THC) have been strong performers lately, with the stock up 34.1% over the past month. The stock hit a new 52-week high of $270.57 in the previous session. Tenet has gained 34.4% since the start of the year compared to …

Earnings To Watch: DocGo Inc (DCGO) Q2 2026 -- GF Value Sees 151% Upside

DocGo Inc (DCGO) is scheduled to release its Q2 2026 earnings on August 17, 2026, with revenue estimated at $75.4 million and an expected loss of $0.06 per share. Analysts have an average target price of $1.88, suggesting a 187.05% upside from the current …

AMN Healthcare Services (NYSE:AMN) Stock Price Expected to Rise, Citizens Jmp Analyst Says

CapsoVision stock rating maintained at Speculative Buy by Benchmark

Benchmark maintained a "Speculative Buy" rating and $10.00 price target on CapsoVision Inc (NASDAQ:CV) despite recent delays in regulatory clearance for its products. The company reported increased usage of its CapsoCam Plus, with FDA clearance for its AI-assisted reading feature expected by Q3, and …

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

BioMarin Pharmaceutical (BMRN) is outperforming the Medical sector and its specific industry year-to-date, with a 15.3% return compared to the sector's 3%. The company holds a Zacks Rank #2 (Buy) due to improving analyst sentiment. Cardinal Health (CAH) is another medical stock showing strong …

Oppenheimer Adjusts PT on Abeona Therapeutics to $21 From $22, Maintains Outperform Rating

Oppenheimer has revised its price target for Abeona Therapeutics (ABEO) to $21 from $22, while reiterating an Outperform rating on the stock. This adjustment comes after Abeona Therapeutics' shares fell following a Q2 earnings miss. The article also provides a company profile, recent news, …

Delcath Systems updates bylaws to designate Delaware courts as exclusive forum

Delcath Systems (NASDAQ:DCTH) has amended its bylaws to designate Delaware courts as the exclusive forum for internal corporate claims and federal district courts for claims under the Securities Act of 1933. This decision, effective immediately, follows a recommendation from the Nominating and Corporate Governance …

Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding

Skye Bioscience is discontinuing its nimacimab obesity program and pursuing a merger with Redx Pharma to form Fibrx Therapeutics, Inc. This strategic shift addresses significant financial strains, as evidenced by a $23.3 million net loss and a substantial doubt about its ability to continue …